BCM
KLDO

Bridgeway Capital Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Bridgeway Capital Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-106,700
Closed -$656K – 1430
2020
Q1 		$656K Sell
106,700
-20,000
-16% -$131K 0.02% 669
2019
Q4 		$636K Buy
+126,700
New +$805K 0.01% 880

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bridgeway Capital Management's KLDO Position: Q2 2020 in Review

Bridgeway Capital Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2020, closing a stake of 106,700 shares — an estimated $656K sold.

Bridgeway Capital Management first reported a position in KLDO in Q4 2019 and held it in 2 quarters. The position peaked at $656K in Q1 2020. 60 funds tracked by Wall St. Rank hold KLDO as of Q2 2020.

  • Bridgeway Capital Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Bridgeway Capital Management sold 106,700 Kaleido Biosciences, Inc. Common Stock shares in Q2 2020, an estimated $656K.
  • Bridgeway Capital Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Bridgeway Capital Management's Kaleido Biosciences, Inc. Common Stock position peaked at $656K in Q1 2020.
  • 60 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2020.

Based on Bridgeway Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.